Last edition
News about "HER2-targeting antibody drug conjugate"
Iksuda Therapeutics Secures FDA IND Clearance for IKS014
Iksuda Therapeutics has received FDA clearance for its IND application for IKS014, a HER2-targeting antibody drug conjugate, paving the way for US site participation in its ongoing Phase 1 trial for advanced HER2-positive solid tumours.
HER2-targeting Antibody Drug Conjugate | 02/07/2025 | By Mrinmoy Dey | 176
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members